LGNDLigand Pharmaceuticals Incorporated

$4B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$37M-33.8% YoY

Gross Profit

$32M87.1% margin

Operating Income

$2M5.8% margin

Net Income

-$15M-42.1% margin

EPS (Diluted)

$-0.91

QoQ Revenue Growth

-49.6%

Cash Flow

Operating Cash Flow

$52M

Free Cash Flow

$47M

Stock-Based Comp.

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$312M

Stockholders' Equity

$793M

Cash & Equivalents

$15M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$37M	$55M	-33.8%
Gross Profit	$32M	$47M	-32.3%
Operating Income	$2M	$5M	-54.8%
Net Income	-$15M	$18M	-185.0%

Revenue Segments

Contract Revenue

$20M22%

Royalty

$14M15%

Material Sales, Captisol

$12M13%

Milestone

$9M10%

Material Sales, Captisol, Core

$6M7%

Material Sales, Captisol, COVID

$6M6%

Contract Revenue, Service

$5M6%

Kyprolis

$5M5%

License Fees

$3M3%

Teriparatide Injection

$3M3%

Evomela

$3M3%

License Fees, Milestones, and Product, Other, Product, Other

$3M3%

Royalty, Other

$2M2%

Rylaze

$2M2%